SAN DIEGO, June 13, 2014 (GLOBE NEWSWIRE) -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company") announced that all of the nominees listed in the management information circular for the annual meeting of shareholders held on Wednesday, June 11, 2014 were elected as directors of the Company.
Detailed results of the vote for the election of directors are set out below.
|Nominees||Votes FOR||% FOR||Votes WITHHELD||%WITHHELD|
|Anthony E. Altig||25,042,861||99.67%||84,058||0.33%|
|Thomas N. Davidson Jr.||24,158,355||96.15%||968,564||3.85%|
|Paul M. Karpecki||25,042,641||99.66%||84,278||0.34%|
|Richard L. Lindstrom||23,851,379||94.92%||1,275,540||5.08%|
|Donald E. Rindell||24,886,166||99.04%||240,753||0.96%|
|Brock J. Wright||24,158,355||96.15%||968,564||3.85%|
About TearLab Corporation
TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.
This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about TearLab. Examples of forward-looking statements in this press release include statements regarding our future recurring revenue expectations and our plans for executing our marketing strategy and building a salesforce, the future potential of the TearLab® Osmolarity System and the related impact on our sales. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2013, filed with the SEC on March 17, 2014, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014, filed with the SEC on May 9, 2014. We do not undertake to update any forward-looking statements.
CONTACT: Stephen Kilmer (647) 872-4849 firstname.lastname@example.orgSource:TearLab Corporation